Skip to the content
Pharmaron Beijing Co., Ltd. reported its financial results for the nine months ended September 30, 2026, stating sales of CNY 12,003.36 million and a net income of CNY 1,247.12 million. The page also lists a separate news item from October
Pharmaron Beijing Co., Ltd. · Beijing, China27 October 2026Partially Verified

Pharmaron Beijing Co., Ltd. reported its financial results for the nine months ended September 30, 2026, stating sales of CNY 12,003.36 million and a net income of CNY 1,247.12 million. The page also lists a separate news item from October

Pharmaron Beijing Co., Ltd. released its earnings report for the first nine months of 2026 on October 27. The company also announced the renewal of a research agreement with Newbay on October 28.

01

What happened

The publication of quarterly financial performance data and the renewal of a specific corporate research contract.

Verification record

Verdict
Partially Verified
Headline supported
Partially Supported
Evidence standing
Partially Verified
Corroboration
Not assessed
  • The material retrieved was the record itself.
  • The source was reachable when the record was checked.
  • Actor confirmed: Pharmaron Beijing Co., Ltd..
  • Date confirmed: 27 October 2026.

Discrepancies

  • The publication of the research agreement renewal occurred on October 28, 2026, not October 27, 2026.
  • The research agreement is with Newbay, not described as a specific corporate research contract renewal in the main financial earnings announcement.
02

What the source states

Pharmaron Beijing Co., Ltd. reported its financial results for the nine months ended September 30, 2026, stating sales of CNY 12,003.36 million and a net income of CNY 1,247.12 million. The page also lists a separate news item from October 28, 2026, noting that the company renewed a research agreement with Newbay.

03

Where it sits in the system

Provides updated financial transparency for a major Beijing-based biotechnology firm, impacting investor assessment of the local life sciences sector.

Boundary of the record

  • ·This record has been read against its source. The reading establishes what the source states, and nothing beyond it.
  • ·The address did not resolve to readable content.
  • ·The address did not resolve to readable content. An unreachable record is not a contradicted one, so the candidate is held rather than rejected.
  • ·The address resolved to a listing page or an unrelated page rather than the record itself, so it is not presented as a source.
  • ·The record confirms part of the claim and not all of it. The difference is carried on the record and displayed with it.
  • ·Located from the listing page at https://www.marketscreener.com/quote/stock/PHARMARON-BEIJING-CO-LTD-103501714/news/, which is preserved as the discovery provenance, and read at its own address.
  • ·Reading established by the recovery worker after the record was held. The evidence is the page at the address recorded here, read against its own statement.

No interpretation is recorded. Discovery produces candidates and stops.

04

What this does not establish

The boundary of the record is stated with it, and travels wherever it is displayed.

Provenance

  1. Source date

    27 October 2026

    When the source is dated.

  2. Observation date

    27 October 2026

    When the event occurred, as the source states it.

  3. Retrieval date

    31 October 2001

    When Lawton obtained the material.

  4. Publication date

    15 November 2026

    When the item entered the feed.

  5. Checked

    15 November 2026

    When the record was read against its source.

05

How we know

The record keeps four dates apart: when the source is dated, when the event occurred, when Lawton obtained the material, and when the item entered the feed. They are not interchangeable, and none is substituted for a missing one.

Where it sits

The intelligence judgment

Corporate signal discovered in Beijing.

Decision state
Not Established
Editorial state
Development